Figure 1



Universal CAR
or
CD28
4-1BB
Anti-delta GK-Fc
Anti-silent Fc
Universal TRAB
Target antigen
CD3
Delta GK-Fc x CD3
Target antigen
or
CD3
Silent Fc x CD3

Figure 2



H0000-G1T3GK/GL4-k0MT
H0000-SG115/GL4-k0MT
Response (0=Baseline)
Time
Affinity of anti-silent Fc antibody for antigen
Affinity of anti-delta GK antibody for antigen

Figure 3-1




Figure 3-2




Figure 4



leader sequence
Anti-silent Fc-VL
linker
Anti-silent Fc-VH
CD8α
CD28
4-1BB
CD3ζ
F2A
EGFP
pMSGV1 anti-silent Fc-CAR

Figure 5-1



E:T=1:1
E:T=1:3
Cancer cell percentage [%]
100
80
60
40
20
0
SK-Hep1 + + + + + +
anti-CH2 CAR + + - + + -
GPC3-SG115 - 10 ug - - 10 ug -

Figure 5-2




E:T=1:1
E:T=1:3
Cancer cell percentage [%]
100
80
60
40
20
0
SK-pca60 + + + + + +
anti-CH2 CAR + + - + + -
GPC3-SG115 - 10 ug - - 10 ug -

Figure 6


Group 1: Vehicle group
Group 2: Anti-GPC3 silent Fc antibody
Group 3: Anti-silent Fc-CAR-T
Group 4: Anti-GPC3 silent Fc antibody and anti-silent Fc-CAR-T
Tumor volume [mm3]
600
500
400
300
200
100
0
0
5
10
15
20
25
30
Group 1
Group 2
Group 3
Group 4